UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934 (Amendment No. 13)*

MARKER THERAPEUTICS, Inc.

(Name of Issuer)

COMMON STOCK, \$0.0010 PAR VALUE PER SHARE

(Title of Class of Securities)

57055L107

(CUSIP Number)

William Sullivan, 10 Market Street, #773 Camana Bay Grand Cayman, KY1-9006 CAYMAN ISLANDS, 345-640-3300 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

March 15, 2021

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of \$240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 57055L107		13D/A	Page 2 of 7
1. NAMES OF REP	ORTING PERSONS I.R.S. IDENTI	FICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
EASTERN CAPI	TAL LIMITED		
	PROPRIATE BOX IF A MEMBER (DF A GROUP	
(see instructions) (a) □			
(b) 🗆			
3. SEC USE ONLY			
4. SOURCE OF FU	NDS (see instructions)		
WC			
	DISCLOSURE OF LEGAL PROCE	EDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)	
6. CITIZENSHIP O	R PLACE OF ORGANIZATION		
CAYMAN ISLAN	DS		
	SOLE VOTING POWER		
NUMBER OF 8. SHARES	SHARED VOTING POWER		
BENEFICIALLY	3,966,668		
OWNED BY EACH 9.	SOLE DISPOSITIVE POWER		
REPORTING	-0-		
PERSON WITH $\frac{10}{10}$	SHARED DISPOSITIVE POWER		
	3,966,668		
11. AGGREGATE AI	IOUNT BENEFICIALLY OWNED B	BY EACH REPORTING PERSON	
3,966,668			
12. CHECK BOX IF (see instructions)		OW (11) EXCLUDES CERTAIN SHARES	
13. PERCENT OF C	LASS REPRESENTED BY AMOUI	NT IN ROW (11)	
5.0%			
	RTING PERSON (see instructions)		
со			

* As of the filing date and as described in Items 4, 5(a) and 5(b), Eastern Capital Limited beneficially owns 3,550,001 shares of Common Stock and 416,667 shares of Common Stock issuable upon exercise of the Series F-1 Warrant.

CUSI	P No. 57055	L107	13D/A	Page 3 of 7
1.	NAMES OF	REPORTING PERSONS I.R.S. ID	ENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
	PORTEOLIC) SERVICES LTD.		
		APPROPRIATE BOX IF A MEME	BER OF A GROUP	
	(see instruct	ions)		
	(a) □			
	(b) SEC USE O			
3.	SEC USE U			
4.	SOURCE O	F FUNDS (see instructions)		
	00			
5.		(IF DISCLOSURE OF LEGAL PR	OCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)	
6.	CITIZENSHI	P OR PLACE OF ORGANIZATION	N	
	CAYMAN IS	LANDS		
		7. SOLE VOTING POWER		
		-0-		
	MBER OF	8. SHARED VOTING POWER		
-	HARES			
	EFICIALLY VNED BY	3,966,668		
-	EACH	9. SOLE DISPOSITIVE POWER	R	
	PORTING	-0-		
PER	SON WITH	10. SHARED DISPOSITIVE POW	/ER	
		3,966,668		
11.	AGGREGAT	E AMOUNT BENEFICIALLY OWN	IED BY EACH REPORTING PERSON	
	3,966,668			
			IN ROW (11) EXCLUDES CERTAIN SHARES	
	(see instruct	ions) 🗆		
13.	PERCENT C	OF CLASS REPRESENTED BY AN	MOUNT IN ROW (11)	
	5.0%			
14.	TYPE OF R	EPORTING PERSON (see instruct	ions)	
	со			

* As of the filing date and as described in Items 4, 5(a) and 5(b), Portfolio Services Ltd. beneficially owns 3,550,001 shares of Common Stock and 416,667 shares of Common Stock issuable upon exercise of the Series F-1 Warrant.

CUSIP No. 57055L107	13D/A	Page 4 of 7
1. NAMES OF REPORTING PERSONS I.R.S. IDENTIF	ICATION NOS. OF ABOVE PERSONS (ENTITIES ONL	Y)
KENNETH B. DART		
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF	F A GROUP	
(see instructions)		
(a) □ (b) □		
3. SÉC USE ONLY		
4. SOURCE OF FUNDS (see instructions)		
00		
	DINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2	.(e)
6. CITIZENSHIP OR PLACE OF ORGANIZATION		
CAYMAN ISLANDS		
7. SOLE VOTING POWER		
-0-		
NUMBER OF 8 SHARED VOTING POWER		
BENEFICIALLY a acc con		
OWNED BY SOLE DISPOSITIVE POWER		
EACH		
REPORTING PERSON WITH -0-		
10. SHARED DISPOSITIVE POWER		
3,966,668		
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY	Y EACH REPORTING PERSON	
3,966,668		
12. CHECK BOX IF THE AGGREGATE AMOUNT IN RO	W (11) EXCLUDES CERTAIN SHARES	
(see instructions) \Box		
13. PERCENT OF CLASS REPRESENTED BY AMOUN	T IN ROW (11)	
5.0%		
14. TYPE OF REPORTING PERSON (see instructions)		
IN		

*As of the filing date and as described in Items 4, 5(a) and 5(b), Kenneth B. Dart beneficially owns 3,550,001 shares of Common Stock and 416,667 shares of Common Stock issuable upon exercise of the Series F-1 Warrant.

CUSIP No. 57055L107

13D/A

Explanatory Note: This Amendment No. 13 to Schedule 13D (this "Amendment No. 13") relates to shares of common stock, par value \$0.0010 per share (the "Common Stock"), of MARKER THERAPEUTICS, Inc., (the "Issuer"). This Amendment No. 13 amends the original Schedule 13D filed with the U.S. Securities and Exchange Commission ("SEC") by the Reporting Persons as previously amended by Amendments No. 1 through 12 (the "Schedule 13D"). Except as otherwise specified in this Amendment No. 13, all previous Items are unchanged. Defined terms used herein but not otherwise defined have the meanings set forth in the Schedule 13D.

Item 4. Purpose of Transaction.

The Reporting Persons sold an aggregate 500,000 shares of the Issuer's Common Stock in open market transactions.

Date	Number of Shares Sold	Weighted Average Selling Price
March 15, 2021	500,000	1.8577 ¹

(1) The Price reported is a weighted average price. These shares of Common Stock were sold through a broker dealer in multiple transactions at prices ranging from \$ 1.85 to \$1.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

The Reporting Persons intend generally to dispose of additional shares of Common Stock, subject to various factors, including but not limited to market conditions and other factors that the Reporting Persons may deem relevant to their investment decisions. However, the Reporting Persons have no specific plans or proposals to dispose of any specific number of shares of Common Stock or at any specific prices and the Reporting Persons reserve the right to change their current intentions. Except as otherwise described above, the Reporting Persons have no plans or proposals that relate to or would result in any transaction, event or action enumerated in paragraph (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer.

Item 5(a) – (c)

As of the date hereof, Eastern Capital Limited beneficially owns 3,966,668 shares of the Issuer's Common Stock, representing 5.0% of the Issuer's outstanding Common Stock. Eastern Capital Limited has shared voting and dispositive power of the shares it beneficially owns with its parent, Portfolio Services Ltd., and Kenneth B. Dart.

Portfolio Services Ltd., as the owner of all the outstanding shares of Eastern Capital Limited, indirectly beneficially owns 3,966,668 shares of the Issuer's Common stock, representing 5.0% of the Issuer's outstanding Common Stock. Portfolio Services Ltd. has shared voting and dispositive power of the shares it beneficially owns.

As a result of Kenneth B. Dart's ownership of all of the outstanding shares of Portfolio Services Ltd., he indirectly beneficially owns 3,966,668 shares of the Issuer's Common Stock, representing 5.0% of the Issuer's outstanding Common Stock. Kenneth B. Dart has shared voting and dispositive power of the shares he beneficially owns.

The percentage ownership is based on 79,303,072 shares of the Issuer's Common Stock outstanding, as at March 15, 2021.

There have been no reportable transactions with respect to the Issuer's Common Stock within the last 60 days by the Reporting Person other than as described in this Statement on Schedule 13D.

CUSIP No. 57055L107

13D/A

Item 5 (d) Not Applicable

ltem 5 (e)

On March 15, 2021, the Reporting Persons ceased to be the beneficial owner of more than five percent of the shares of Issuer's Common Stock.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

Item 6 is hereby amended and supplemented as follows:

The information set forth in Item 4 of this Amendment No. 13 is incorporated by reference into this Item 6.

Item 7. Material to Be Filed as Exhibits.

Exhibit 1 – Joint Filing Agreement

CUSIP No. 57055L107

13D/A

Page 7 of 7

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

EASTERN CAPITAL LIMITED

03/15/2021 Date /s/ Kenneth B. Dart Signature Kenneth B. Dart, Director Name/Title PORTFOLIO SERVICES LTD. 03/15/2021 Date /s/ Kenneth B. Dart Signature Kenneth B. Dart, Director Name/Title **KENNETH B. DART** 03/15/2021 Date /s/ Kenneth B. Dart Signature Kenneth B. Dart Name/Title

EXHIBIT 1

JOINT FILING AGREEMENT

The undersigned agree to the joint filing of Schedule 13D (including any and all amendments thereto) with respect to the shares of common stock of Marker Therapeutics, Inc. The undersigned further agree and acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the other, except to the extent that it knows or has reason to believe that such information is inaccurate.

EASTERN CAPITAL LIMITED 03/15/2021
Date
/s/ Kenneth B. Dart
Signature
Kenneth B. Dart, Director
Name/Title
PORTFOLIO SERVICES LTD.
03/15/2021
Date
/s/ Kenneth B. Dart
Signature
Kenneth B. Dart, Director
Name/Title
Name/ me
KENNETH B. DART
03/15/2021
Date
/s/ Kenneth B. Dart
Signature
Kenneth B. Dart
Name/Title